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Abstract
Successful antiretroviral pre-exposure prophylaxis (PrEP) for mucosal and intravenous HIV-1 transmission could reduce new
infections among targeted high-risk populations including discordant couples, injection drug users, high-risk women and men
who have sex with men. Targeted antiretroviral PrEP could be particularly effective at slowing the spread of HIV-1 if a single
antiretroviral combination were found to be broadly protective across multiple routes of transmission. Therefore, we designed
our in vivo preclinical study to systematically investigate whether rectal and intravenous HIV-1 transmission can be blocked by
antiretrovirals administered systemically prior to HIV-1 exposure. We performed these studies using a highly relevant in vivo
model of mucosal HIV-1 transmission, humanized Bone marrow/Liver/Thymus mice (BLT). BLT mice are susceptible to HIV-1
infection via three major physiological routes of viral transmission: vaginal, rectal and intravenous. Our results show that BLT
mice given systemic antiretroviral PrEP are efficiently protected from HIV-1 infection regardless of the route of exposure.
Specifically, systemic antiretroviral PrEP with emtricitabine and tenofovir disoproxil fumarate prevented both rectal (Chi
square=8.6, df=1, p=0.003) and intravenous (Chi square=13, df=1, p=0.0003) HIV-1 transmission. Our results indicate that
antiretroviral PrEP has the potential to be broadly effective at preventing new rectal or intravenous HIV transmissions in
targeted high risk individuals. These in vivo preclinical findings provide strong experimental evidence supporting the potential
clinical implementation of antiretroviral based pre-exposure prophylactic measures to prevent the spread of HIV/AIDS.
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Introduction
Preventing the spread of HIV to new individuals is critical to
stopping the HIV/AIDS pandemic. However, few successful
strategies to prevent HIV transmissions currently exist [1–5].
Novel approaches to prevent HIV transmission, including effective
vaccines, are being considered and developed [6]. In particular,
antiretroviral pre-exposure prophylaxis (PrEP) has been postulated
to be a potentially highly effective prevention modality [7–15].
There are many reasons to consider implementing targeted
antiretroviral PrEP until less toxic, easier to deliver and more
potent prevention methods become available. Candidate antiret-
roviral drugs for PrEP already exist. Antiretrovirals to prevent
vertical HIV transmission are already used clinically. In 2007,
500,000 (,33%) HIV positive pregnant women worldwide
received antiretrovirals to prevent HIV transmission between
them and their children [5]. Additionally, PrEP is a prevention
approach that can be discretely utilized without requiring partner
consent. While PrEP comes with associated costs, these should not
distract from the vast prospective positive impact of PrEP: targeted
PrEP has been mathematically modeled to avert up to 3 million
new infections over a 10 year period in Sub-Saharan Africa alone
[16]. Antiretroviral PrEP could benefit numerous groups at risk of
either vaginal, rectal or intravenous HIV exposure: discordant
couples, high risk women, men who have sex with men and
injection drug users [13]. Topical microbicides may be identified
that block mucosal HIV transmission [17–19]. However, as
illustrated by several setbacks in recent clinical trials (i.e.
Microbicides Development Program study 301using 0.5% Pro
2000/5) microbicide development and implementation lags far
behind that of clinically approved antiretrovirals [13,20,21]. In
addition, it should be noted that topical interventions will not
prevent intravenous HIV transmission. The diversity of the groups
targeted for PrEP highlights the need for broad prevention
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overlapping ways by which an individual may become exposed
to HIV.
We performed comprehensive efficacy studies to determine
whether a single antiretroviral PrEP approach can protect from
multiple routes of HIV transmission using a uniform and highly
relevant experimental platform. When choosing a model system to
perform PrEP efficacy studies, it was important to identify critical
characteristics that the system would have to exhibit in order to
study HIV prevention modalities. Such a model would permit
studying the interplay between de novo generated human immune
cells and HIV being transmitted via physiological routes in the
context of highly active antiretroviral drugs. In addition, such a
model should be affordable, available to many investigators and
capable of providing relatively rapid feedback on the efficacy of
any intervention being evaluated. To this end, we chose the
humanized Bone marrow/Liver/Thymus (BLT) mouse as our
experimental system [22].
Humanized BLT mice are individually bioengineered to exhibit
a complete, systemic, self-renewing reconstitution of all major
human hematopoietic lineages including T, B, monocyte/
macrophage, dendritic and natural killer cells that facilitates the
generation of functional human immune responses [22–26]. The
levels of HIV receptor and co-receptor expression in BLT mice
reflect those observed in humans and the pathogenesis of CCR5
tropic HIV-1 in BLT mice mirrors descriptions of HIV
pathogenesis in infected individuals [24,26]. Particularly relevant
to this study is the broad and systemic reconstitution of BLT mice
with human immune cells necessary for HIV-1 replication and
transmission (CD4
+ T cells, macrophages and dendritic cells) that
encompasses the peripheral blood and the rectal and vaginal
mucosa rendering BLT mice susceptible to intravenous and
mucosal HIV-1 infection [22,24,26]. Furthermore, systemic PrEP
with a combination of antiretrovirals (FTC: emtricitabine and
TDF: tenofovir disoproxil fumarate) prevents vaginal HIV-1
transmission in BLT mice establishing this model as a novel
system for in vivo preclinical evaluation of HIV prevention
modalities [24].
To date, the majority of HIV prevention research has focused
on the assessment of the safety and effectiveness of products
capable of preventing HIV transmission via the vaginal compart-
ment. Receptive anal intercourse is common among men who
have sex with men and rectal transmission is a major driving force
of the AIDS pandemic [5]. In addition, rectal transmission is also
likely to account for a significant number of transmissions to
women [27]. We hypothesized that systemic antiretroviral PrEP
can provide protection from rectal and intravenous HIV-1
transmission. We tested this hypothesis by treating BLT mice
systemically with FTC/TDF prior to exposure and we determined
that antiretroviral PrEP can prevent rectal and intravenous HIV-1
transmission. Our in vivo preclinical efficacy data shows that
systemic antiretroviral PrEP provides strong protection against
HIV-1 infection regardless of the route of transmission.
Materials and Methods
Preparation of Humanized BLT Mice, Tissue Harvesting
and Microscopic and Flow Cytometric Analyses
BLT mice were prepared essentially as previously described
[22–26]. Briefly, thy/liv implanted [28] NOD/SCID or NOD/
SCID-gamma chain null mice (The Jackson Laboratories, Bar
Harbor, ME) were transplanted with autologous human fetal liver
CD34
+ cells (Advanced Bioscience Resources, Alameda, CA) and
monitored for human reconstitution in peripheral blood by flow
cytometry [22,24,26]. Mice were maintained at the Animal
Resources Center of University of Texas Southwestern Medical
Center (UTSWMC) in accordance with protocols approved by the
UTSWMC Institutional Animal Care and Use Committee.
Tissues were harvested and then evaluated by molecular,
microscopic and flow cytometric analyses for evidence of HIV
infection as we have previously described [22,24,26]. Briefly,
minced and/or digested tissues were disrupted and filtered
through a 70 mm cell strainer. Liver and lung mononuclear cells
were isolated using a Percoll gradient. In other tissues, red blood
cells were lysed (ACK lysing buffer). Once isolated, mononuclear
cells were washed, enumerated and utilized in the indicated assays
described below.
Systemic Application of FTC/TDF and Exposure of BLT
Mice to HIV-1
Stocks of HIV-1JR-CSF [29] were prepared, titered and p24
content was determined as we have previously described [30,31].
Briefly, virus supernatants were collected following transient
transfection of 293T cells with the plasmid molecular clone of
JR-CSF. Supernatant p24 content was determined by ELISA
(Coulter, kit sensitivity: 7.8 pg/ml). HIV-1 exposures were
performed essentially as previously described using a total volume
of 2–10 mL (rectal: 170 ng p24) or 200 mL (intravenous: 58 ng
p24) [26,32]. Intravenous HIV-1 exposures were administered via
the tail vein. FTC/TDF dosing was based on published efficacy in
BLT mice [24]. To prepare FTC/TDF for BLT mouse
administration TruvadaH capsules (Gilead, Foster City, CA) were
dissolved in deionized water with 10% DMSO then sterile filtered
(0.22mm). FTC and TDF concentrations were initially estimated
by UV spectrophotometry and then confirmed by mass spectros-
copy (UTSW Chemistry Core). The FTC/TDF solution was
administered intraperitoneally (daily injections of 3.5 mg FTC and
5.2 mg TDF) prior or subsequent to exposure to HIV-1, as
indicated in Figure 1A and the text [24,33–35].
Analysis of HIV-1 Infection of BLT Mice
In this study, the primary endpoint was determining whether a
given intervention protected BLT mice from HIV-1 transmission.
To ensure that the most stringent criteria were met by the
intervention, we designed a high threshold defining ‘‘protection’’.
We defined ‘‘protection’’ in treated groups as the complete
absence of any evidence of infection, such that protected mice had
no positive results for the presence of HIV by any method of
analysis at any time point tested. A positive result for the presence
of HIV-1 from any treated animal by any method indicated a lack
of protection referred to as ‘‘breakthrough’’ infection.
Infection of BLT mice with HIV-1 was monitored in peripheral
blood by determining plasma levels of viral antigenemia (ELISA
p24, Coulter, assay sensitivity: 7.8 pg/ml), levels of viral RNA in
plasma (Amplicor, Roche, assay sensitivity of 400 RNA copies per
ml) and levels of viral DNA in peripheral blood cells (real time
PCR analysis, assay sensitivity of 10 copies) as previously described
[22,24,26,31]. Analysis for systemic infection was performed on
tissues harvested from infected mice or on cells isolated from the
indicated tissues utilizing in situ hybridization, real time PCR
analysis and co-culture with PHA activated allogeneic human
PBMC as previously described [22,24,26]. In the case of
breakthrough infection, it is possible that any developed drug
resistance mutants could revert back to wild-type in the absence of
drug selection following the completion of PrEP. Therefore, to
increase our likelihood of detecting any developed resistance
mutants we performed our sequence analysis on DNA samples
from the earliest possible time point at which HIV-1 DNA was
PrEP for HIV-1 Transmission
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gene from cell-associated HIV-1 DNA amplification products to
evaluate whether these transmission events resulted from drug
resistant variants. No described resistance mutations in reverse
transcriptase were observed [36–39].
Statistical Analysis
All statistical analyses (alpha level: 0.05) were performed in
Prism version 5 (Graph Pad Software, Inc., San Diego, CA).
Kaplan-Meyer plots indicate the percentage of animals that are
HIV-1 positive in the peripheral blood by each time point. Tick
marks on the curves represent the time point at which HIV-1
negative animals were censored from the analysis.
Results
This study models application of antiretroviral PrEP in a
manner that closely resembles planned or ongoing PrEP clinical
trials evaluating the efficacy of TruvadaH [FTC co-formulated
with TDF] [13]. Systemic PrEP models routine daily systemic
administration of antiretrovirals (not temporally associated with a
specific high-risk event) that continues until a general behavior
pattern of high-risk actions ceases. Systemic PrEP dosing in the
BLT mice continued for 4 days following exposure to simulate
how systemic PrEP is expected to continue beyond the last high
risk action for a given period before a person would stop the
regimen (Figure 1A). Once BLT mice were generated, but prior to
HIV-1 exposure, we analyzed their peripheral blood to determine
their reconstitution with human cells and their suitability for these
studies. All the humanized BLT mice used for these experiments
had high levels of human lymphoid (CD45
+) cells in their
peripheral blood (51.0%616.8 SD, n=46) (Figure 1B). In
addition, all mice were reconstituted with high levels of human
CD4
+ T cells in peripheral blood (Figure 1C).
Systemically Administered Antiretroviral PrEP Prevents
Rectal HIV-1 Transmission
We have previously shown that systemic PrEP efficiently blocks
vaginal HIV-1 transmission in BLT mice [24]. Here we sought to
determine whether systemic PrEP also can prevent rectal HIV-1
transmission. As depicted in Figure 1A, test BLT mice (n=9) were
exposed to a single dose of HIV-1 (CCR5-tropic primary isolate
JR-CSF [29]) on the third of seven days of consecutive dosing with
FTC/TDF. After rectal HIV-1 exposure, BLT mice were followed
over time to determine if transmission had occurred. Transmission
was defined using most stringent criteria: any single evidence of
infection by any method of detection at any of the time points
analyzed. Protection was also defined by very stringent criteria:
complete lack of evidence of infection, by any method of detection
at any of the time points analyzed, including a systemic post-
mortem analysis. Using this criteria, none of the samples evaluated
from rectally challenged animals also receiving systemic FTC/
TDF showed evidence of plasma viral RNA (Amplicor), PBMC-
associated HIV-1 DNA (real time PCR), plasma antigenemia
(ELISA) or loss of peripheral CD4
+ T cells (flow cytometry). In
contrast, 12 of 19 non-treated control mice became HIV-1 positive
(Log-rank [Mantel Cox] Test: Chi square=8.6, df=1, p=0.003)
(Figure 2A–D; Table 1). These data indicate that systemically
Figure 1. Experimental design and reconstitution of BLT mice with human hematopoietic cells. (A) Systemic PrEP with FTC/TDF (daily
administrations for 7 consecutive days) to prevent rectal, intravenous and vaginal HIV-1 transmission. Viral exposure was performed 3 hours following
the third FTC/TDF dosing. (B) Peripheral blood human leukocytes (CD45
+) levels in each of the groups of BLT mice used. (C) Peripheral blood human T
lymphocytes (CD4
+ and CD8
+) levels in each of the groups of BLT mice used. Box-plot interpretation for this and subsequent figures: middle line is the
median; box extends from the 25
th to the 75
th percentiles; error bars extend down to the lowest value and up to the highest value.
doi:10.1371/journal.pone.0008829.g001
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transmission in humanized BLT mice.
We confirmed the lack of rectal HIV-1 transmission in BLT
mice treated systemically with FTC/TDF using a comprehensive
set of highly sensitive analytical techniques aimed at detecting the
presence of HIV-1 in tissues. Specifically, we analyzed several
tissues from these mice for evidence of viral RNA expression (in
situ hybridization), replication competent virus (co-culture with
activated allogeneic PBMC) or viral DNA (real time PCR). All
tissues analyzed by each method for each mouse are detailed in
Table 1. Whereas HIV-1 infection was confirmed by in situ
hybridization for the presence of productively infected cells in
tissues from the infected non-treated control mice, no productively
infected cells were detected in the tissues obtained from the
systemic PrEP treated mice (Figure 3A & B; Table 1). We also
tested for the presence of cells containing replication competent
HIV-1 with a co-culture virus rescue assay utilizing PHA/IL2
activated allogeneic PBMC. Whereas virus was rescued from cells
originating in the tissues of infected non-treated mice, no virus was
rescued from any tissues from the protected mice treated with
antiretrovirals (Figure 3C; Table 1). Finally, real time PCR
analysis of DNA obtained from cells isolated from tissues of
infected non-treated control mice demonstrated the presence of
viral DNA. In contrast, none of the mice receiving systemically
applied antiretroviral PrEP exhibited viral DNA in tissues
(Figure 3D; Table 1). In summary, these results demonstrate the
absence of any evidence of HIV infection following systemic
administration of antiretrovirals prior to exposure in humanized
BLT mice.
Systemic Administration of Antiretrovirals Results in
Protection from Intravenous HIV-1 Infection
Having established the ability of systemic PrEP to prevent
mucosal HIV-1 transmission, we sought to determine whether
systemic PrEP could also prevent intravenous HIV-1 infection.
During intravenous exposure no mucosal surfaces must be
overcome by the virus in order to establish infection. Therefore,
infection can potentially be established simultaneously in numer-
ous sites throughout the body rendering protection from
intravenous HIV-1 exposure much more difficult to achieve. We
assessed the efficacy of systemically applied antiretrovirals to
prevent intravenous HIV-1 transmission in BLT mice by
administering a seven-day course of systemic PrEP with FTC/
TDF as described previously for the vaginal and above for the
Figure 2. Systemic PrEP with FTC/TDF prevents rectal HIV-1 transmission. (A) Kaplan-Meier plot of the time course to peripheral blood
conversion following rectal HIV-1 exposure in BLT mice with or without pre-exposure treatment with systemic FTC/TDF. (B) Plasma viral RNA was only
detected in infected non-treated control mice. Mice receiving systemic PrEP were negative for plasma viral RNA. Thin dashed line represents the limit
of detection for this assay. (C) PBMC-associated viral DNA was only detected in infected non-treated control mice. Mice receiving systemic PrEP were
negative for PBMC-associated viral DNA. (D) Average levels of human CD4
+ T cells in peripheral blood showed a loss of CD4
+ T cells in infected non-
treated control mice, but not in systemic PrEP treated BLT mice. Note that regardless of the assay utilized there was no evidence of rectal infection in
any of the mice receiving systemic PrEP with FTC/TDF.
doi:10.1371/journal.pone.0008829.g002
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mice (n=8) intravenously to a single dose of HIV-1JR-CSF 3 hours
after the administration of the third of 7 consecutive daily doses of
FTC/TDF (Figure 1A).
Consistent withthehigh efficiencyoftransmissionassociated with
thistypeofexposure,inthe absence oftreatmentweobserved 100%
transmission after intravenous inoculation (6/6) (Figure 4A–D;
Table 2). In addition, we observed that intravenous infection could
be delayed, but not prevented, when BLT mice (n=4) were
administered the 7 day treatment with FTC/TDF 24 hours
following intravenous exposure to the same dose of HIV-1 (Log-
rank[MantelCox]Test:Chisquare=9,df=1,p=0.003)(Table2).
Table 1. Description of BLT mice used to evaluate systemic PrEP for rectal HIV-1 transmission.*
Mouse # In PB at exposure:
Weeks
followed
(exposure
to harvest) Peripheral Blood Analysis Multiple Tissue Analysis
%h u m a n
CD45
+
%h C D 4 5
+
hCD3
+
hCD4
+
Plasma
antigenemia
(Gag
p24)
A
Plasma viral
load (RNA)
B
PBMC
associated
viral DNA
C
Included
in Figure
2B–D
In situ
hybridization
for viral RNA
Quantitative
Real time
PCR for cell
associated
viral DNA
C
Virus
rescue of
replication
competent
virus
(Gag
p24)
A
No Drug 14 0 7 5 3 Pos (2 of 3) Pos (1 of 1) Pos (1 of 1) Yes frt,L.int,lu,mln,
o,S.int,s,st
b,li,lu,o,s b,li,lu,o
22 2 7 6 3 Pos (2 of 3) Pos (1 of 1) Pos (2 of 2) Yes nd nd nd
36 2 8 2 3 Pos (1 of 2) Pos (1 of 1) Pos (1 of 2) Yes s b,li,lu,o,s b,li,lu,o,s
44 3 8 8 4 Pos(1 of 2) Pos (1 of 1) Pos (1 of 2) Yes nd nd b,li,lu,s
56 9 8 2 6 Pos (3 of 3) Pos (1 of 1) Pos (3 of 3) Yes lu,o,pln,r,s b,li,lu,o,s b,li,lu,o,s
66 3 8 4 7 Pos (6 of 7) Pos (1 of 1) Pos (5 of 6) Yes mrt,lu b,li,lu,o,s b,li,lu,o,s
77 3 8 2 7 N e g ( 0 o f 4 )n d n d N o n d n d n d
82 7 7 8 8 N e g ( 0 o f 8 )n d n d N o n d n d n d
92 0 8 2 9 Pos (5 of 5) Pos (1 of 1) Pos (4 of 5) Yes s b,li,lu,o,s b,lu,o,s
10 64 72 10 Neg (0 of 10) nd nd No nd nd nd
11 22 71 11 Pos (11 of 11) Pos (1 of 1) Pos (9 of 10) Yes nd b,li,lu,o,s nd
12 63 86 11 Neg (0 of 6) nd nd No nd nd nd
13 80 86 11 Pos(7 of 7) Pos (1 of 1) Pos (7 of 7) Yes s b,li,lu,o,s b,li,lu,o,s
14 58 91 12 Pos (5 of 8) Pos (1 of 1) Pos (8 of 8) Yes s b,li,lu,o,s b,li,lu,o,s
15 59 90 12 Neg (0 of 6) nd nd No nd nd nd
16 43 76 14 Pos (13 of 14) Pos (1 of 1) Pos (11 of 13) Yes nd b,li,lu,o b,li,lu,o
17 39 63 14 Pos (12 of 14) Pos (1 of 1) Pos (10 of 12) Yes nd nd b,li,lu,o,s
18 31 66 14 Neg (0 of 14) nd nd No nd nd nd
19 61 94 15 Neg (0 of 9) nd nd No s nd nd
FTC/TDF 20 60 87 4 Neg (0 of 2) Neg (0 of 1) Neg (0 of 2) Yes nd b,li,lu,o,s b,li,lu,o,s
21 67 89 6 Neg (0 of 3) Neg (0 of 2) Neg (0 of 3) Yes nd b,li,lu,o,s b,li,lu,o,s
22 68 79 8 Neg (0 of 4) Neg (0 of 2) Neg (0 of 4) Yes nd b,li,lu,o,s b,li,lu,o,s
23 52 91 9 Neg (0 of 6) Neg (0 of 2) Neg (0 of 5) Yes s b,li,lu,o,s b,li,lu,o,s
24 44 88 10 Neg (0 of 4) Neg (0 of 2) Neg (0 of 4) Yes nd b,li,lu,s b,li,lu,s
25 42 76 12 Neg (0 of 5) Neg (0 of 2) Neg (0 of 5) Yes L.int,o,pln,S.int.,s b,li,lu,o,s b,li,lu,o,s
26 63 88 12 Neg (0 of 7) Neg (0 of 2) Neg (0 of 6) Yes s b,li,lu,o,s b,li,lu,o,s
27 42 88 12 Neg (0 of 7) Neg (0 of 2) Neg (0 of 6) Yes s b,li,lu,o,s b,li,lu,o,s
28 38 86 15 Neg (0 of 8) Neg (0 of 2) Neg (0 of 8) Yes s b,li,lu,o,s b,li,lu,o,s
Mean
(+/2SD)
51%
(+/217)
82%
(+/28)
9
(+/24)
*The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold used to highlight that HIV-1 was found in the
indicated tissues. Numbers in parenthesis: first number represents the number of positive results out of the second number, which represents the number of different
time points (total samples) tested. b – bone marrow; frt – female reproductive tract; li – liver; L.int – large intestine; lu – lung, mln – mesenteric lymph node; mrt – male
reproductive tract; nd - not done; neg – negative; o – thymic organoid; pb – peripheral blood; pln – peripheral lymph node; pos – positive; r – rectum; S.int – small
intestine; s – spleen; st – stomach.
AELISA limit of detection=7.8 pg/ml.
BAmplicor limit of detection=400 copies/ml.
CReal-time PCR limit of detection=10 copies.
doi:10.1371/journal.pone.0008829.t001
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8829Figure 3. Systemic analyses of the protection afforded by FTC/TDF from rectal HIV-1 transmission. (A) Tissues from a representative
non-treated control mouse (#1) showed the presence of productively HIV-1 infected cells expressing detectable viral RNA. (B) Tissues from a mouse
receiving systemic PrEP (#25) demonstrated a complete lack of productively infected cells in any of the tissues analyzed. Black foci represent cells
producing viral RNA (bar=50 mm). (C) Tissues from infected non-treated control mice were positive for replication competent HIV-1 when co-
cultured with activated allogeneic PBMC. Tissues from mice receiving systemic PrEP were consistently negative for the presence of HIV-1. Presence of
replication competent virus was indicated by the detection of viral p24 in the culture supernatant. (D) Tissues from infected non-treated control mice
were positive for HIV-1 DNA by real time PCR analysis. Tissues from mice that received systemic PrEP were consistently negative for the presence of
HIV-1 DNA. Thin dashed lines represent the limit of detection for the respective assays.
doi:10.1371/journal.pone.0008829.g003
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treated, infected mice demonstrated the absence of mutations
associated with resistance to either FTC or TDF [37]. All tissues
analyzed by each method for each of the mice used for these
experiments are detailed in Table 2. In all cases, infection was
confirmed by every criterion utilized (Figures 4 and 5; Table 2).
In sharp contrast with the results described above, we observed
protection from intravenous infection in 7 of 8 BLT mice that
received the seven day course of systemic PrEP with FTC/TDF.
Protection was determined by each of the following criteria: the
lack of HIV-1 plasma antigenemia, PBMC-associated viral DNA,
loss of CD4
+ T cells or plasma viral RNA (Log-rank [Mantel Cox]
Test: Chi square=13, df=1, p=0.0003) (Figure 4A–D; Table 2).
Comprehensive analyses of different tissues from these mice
further confirmed that they were indeed fully protected from
infection (Figure 5A–C, all tissues analyzed by each method are
detailed in Table 2). In the case of the single breakthrough
transmission (mouse #42), sequence analysis of the entire reverse
transcriptase gene indicated that transmission was not due to the
development of drug resistance [37]. Together, these results
demonstrated that systemic administration of FTC/TDF PrEP
can efficiently prevent intravenous infection with HIV-1 and
illustrates the significant potential of PrEP to prevent intravenous
HIV transmission in humans.
Discussion
In this manuscript, we provide in vivo preclinical evidence
supporting the hypothesis that systemic antiretroviral PrEP can
provide broad protection from HIV transmission. Our results
obtained using a highly relevant in vivo model of HIV transmission
show that systemic antiretroviral PrEP can effectively prevent
rectal and intravenous HIV-1 infection. It is important to note that
systemic antiretroviral PrEP with a single drug combination
prevents infection of BLT mice by the three most common routes
of human HIV-1 transmission. The highly encouraging results
from this comprehensive evaluation of antiretroviral PrEP efficacy
serve as strong proof of principle for this approach and have major
implications for the continued planning and implementation of
future and current PrEP studies.
Approaches aimed at obtaining protection from all potential
modes of transmission are highly significant. Individually,
unprotected vaginal intercourse accounts for the vast majority of
new HIV transmissions globally [40]. Rectal HIV exposure
Figure 4. Systemic PrEP with FTC/TDF results in effective protection from intravenous HIV-1 transmission. (A) Kaplan-Meier plot of the
time course to peripheral blood conversion following intravenous exposure to HIV-1 in BLT mice with or without systemic PrEP. (B) Seven (out of
eight) mice receiving systemic PrEP were consistently negative for plasma viral RNA. Plasma viral RNA was detected in the systemic PrEP
breakthrough mouse (#42) and the 6 non-treated control mice. Thin dashed line represents the limit of detection for this assay. (C) BLT mice
receiving systemic PrEP were negative for PBMC-associated viral DNA by real time PCR. PBMC-associated viral DNA was detected in the systemic PrEP
breakthrough mouse (#42) and the 6 non-treated control mice. (D) Average levels of human CD4
+ T cells in peripheral blood showed loss of CD4
+ T
cells in the systemic PrEP breakthrough mouse (#42) and the 6 non-treated control mice. CD4
+ T cells remained constant in the protected systemic
PrEP treated BLT mice.
doi:10.1371/journal.pone.0008829.g004
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8829accounts for the majority of HIV transmission events in the United
States and other developed nations [41]. Even though rectal HIV
exposure is the main mode of transmission among men who have
sex with men, this route is also likely to account for a significant
number of transmissions to women [27]. Intravenous HIV
exposure occurs primarily among injection drug users and is a
growing health concern in many nations [42]. Unlike mucosal
exposure with its intrinsic physical and biological barriers, the
direct exposure of virus to the blood stream results in more
efficient transmission. Our results provide clear pre-clinical
evidence of the potential usefulness of systemic PrEP for
intravenous transmission. The ability to prevent HIV-1 transmis-
sion by all three routes using one drug combination has the
potential of greatly facilitating the global implementation of
preventative measures.
Until this study, in vivo preclinical data substantiating a broad
prevention approach using a single drug combination to prevent
three routes of transmission had been lacking. In vivo data on the
efficacy of PrEP with FTC/TDF had been limited to two reports
relating to mucosal transmission. In one study, we showed that
systemic PrEP with FTC/TDF can effectively prevent vaginal
HIV-1 transmission in BLT mice [24]. The second study used
rhesus macaques to show that intermittent or daily systemic PrEP
with FTC/TDF can protect from rectal SHIV transmission in a
low-dose repeat exposure model [43]. Collectively, these two
reports and the current data show that antiretroviral PrEP with
FTC/TDF can afford extensive protection from vaginal, rectal
and intravenous HIV-1 transmission.
When considering such broad use of antiretrovirals as
prophylaxis, there is an issue of major importance that must be
Figure 5. Systemic analyses of the protection afforded by FTC/TDF from intravenous HIV-1 transmission. (A) In situ hybridization
analysis in spleens showed productively infected cells in a representative non-treated control mouse (#29) and the systemic PrEP breakthrough
mouse (#42). In contrast, no productively infected cells were identified in the spleen of a representative systemic PrEP protected mouse (#38). Black
foci represent cells producing viral RNA (bar=50 mm). (B) Tissues from mice protected by systemic PrEP were consistently negative for the presence
of HIV-1 when co-cultured with activated allogeneic PBMC. Replication competent HIV-1 was detected in the systemic PrEP breakthrough mouse
(#42) and the 6 non-treated control mice. Presence of replication competent virus is indicated by the detection of viral p24 in the culture
supernatant. (C) Tissues from mice given systemic PrEP were consistently negative for the presence of HIV-1 DNA by real time PCR. HIV-1 DNA was
detected in the systemic PrEP breakthrough mouse (#42) and the 6 non-treated control mice. Thin dashed lines represent the limit of detection for
the respective assays.
doi:10.1371/journal.pone.0008829.g005
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PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8829addressed. In humans, lack of strict compliance to PrEP regimens
could increase the likelihood of drug resistance being developed in
the event of breakthrough infection. Therefore broad antiretrovi-
ral use can result in increased emergence of resistance to the
drug(s) when infections do occur [11]. Spread of resistant viruses
could limit the efficacy of current therapeutic interventions using
these same drugs, although it should be noted that the fitness of
multidrug resistant viruses for mucosal transmission has yet to be
fully established. Future BLT mouse studies could model lack of
compliance to evaluate the fitness of multidrug resistant viruses for
mucosal transmission and explore potential mechanisms of
breakthrough infections. Despite the high protection observed
while using PrEP (.88%), our results indicated one breakthrough
infection observed in one animal infected intravenously. It should
be noted that sequence analysis of the entire reverse transcriptase
gene revealed that this one transmission event was not the direct
result of the appearance of mutations associated with drug-
resistance [37]. The molecular basis for transmission of wild type
virus after venous exposure in the presence of PrEP remains to be
determined.
Results obtained using humanized BLT mice must be
considered in the context of previous studies of antiretrovirals
for HIV prevention performed in other models such as non-
human primates. Experiments performed using non-human
primates have provided evidence for the use of tenofovir (PMPA)
to prevent intravenous infection by SIVmne in long-tailed
macaques [44] and successful antiretroviral PrEP in rhesus
macaques exposed rectally to either SIVmac251/32H or
SHIVSF162P3 have also been reported with this compound
[45,46]. Topical and systemic PrEP with one or more fusion
inhibitors protected from vaginal SHIV transmission in rhesus
macaques [47,48]. Systemic PrEP with FTC/TDF was shown to
prevent rectal SHIV transmission in rhesus macaques [43] and in
yet another non-human primate model, 2 pig-tailed macaques
were protected from intravenous challenge with simian-tropic
HIV (stHIV) by systemic PrEP with efavirenz plus FTC/TDF
[49]. Additional preclinical studies in macaques testing antiretro-
viral HIV-1 prevention modalities have focused on post-exposure
prophylaxis, not pre-exposure regimens [44,50–54]. The use of
multiple animal models and different classes/combinations of
drugs in these studies makes it difficult to make direct comparisons
and to extrapolate potential outcomes. The current study
represents a significant advance because it has produced a data
set that can be easily interpreted and easily compared across
multiple virus transmission routes all within the same experimental
platform.
While our findings and those from non-human primate research
suggest that antiretroviral PrEP can prevent HIV transmission,
neither model has been shown to predict efficacy or safety in
humans. This limitation exists because there is still no evidence of
efficacy for antiretrovirals in preventing vaginal, rectal or
intravenous transmission in humans [7,10,12,15,55]. It will be
essential that ongoing human clinical trial data be compared to
BLT and non-human primate studies in order to validate these
useful models. Protection is likely to be dependent on the drug
exposure levels achieved following dosing of the PrEP antiretro-
virals. Currently, there is no comparative pharmacological data of
these levels between humans and BLT mice. Since protection is
dependent on the dose of FTC/TDF it will be important to define
the drug exposure of the regimen in BLT mice, and assess its
relationship to the drug exposure achieved after oral dosing with
Truvada in humans. Detailed information on the drug exposure in
BLT mice will be important for interpreting the efficacy results in
this model and for comparison with efficacy data from human
trials when these become available in the near future. These data
might help assess the relationship between drug exposure achieved
after oral dosing with Truvada in humans and its effectiveness in
ongoing clinical trials. In addition, a significant strength of
humanized BLT mice is the fact that they can be used in future
studies to address other potential variables between BLT mice and
humans including differences in timing of dosing, drug concen-
trations, adherence to drug regimens, virus inoculum and relevant
co-infections. Our results also suggest that humanized BLT mice
will be useful for the evaluation of topical microbicides and to
provide preclinical evidence for their potential success. The
availability of a small animal model such as BLT mice for
screening prevention modalities prior to or in conjunction with
macaque and human studies is a great asset to the field [56].
In conclusion, we provide preclinical evidence regarding the
potential efficacy of an antiretroviral pre-exposure prophylactic
approach to prevent vaginal, rectal and intravenous HIV-1
transmission. Our results provide strong support for the continued
implementation of clinical trials using targeted antiretroviral pre-
exposure prophylaxis for all the major routes of HIV transmission
contributing to the HIV/AIDS pandemic.
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